Kala Bio, Inc. (KALA)
Nasdaq: KALA · Pharmaceutical Preparations · Arlington, MA · filing with the SEC since 2009
Who owns Kala Bio, Inc.
As filed with the SECHolders of 5% or more
3
Oxford Finance LLC holds 16.5% of Common Stock, $0.001 par value per share, as its SCHEDULE 13G filed Dec 3, 2025 says.
Directors and officers
11
report now, of 30 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Oxford Finance LLC
SCHEDULE 13G · filed Dec 3, 2025 · Common Stock, $0.001 par value per share
LifeSci Capital LLC
SCHEDULE 13G · filed Jan 13, 2026 · Common Stock, $0.001 par value per share
Labkowski Nachum
SCHEDULE 13G · filed Oct 19, 2026 · Common Stock, $0.001 par value
ADAR1 Capital Management, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
SR One Capital Fund II Aggregator, LP
SCHEDULE 13D/A · filed Oct 15, 2025 · Common Stock, $0.001 par value · reported falling below 5%, from 5.5% in Oct 1, 2025
Lazar David E.
SCHEDULE 13D/A · filed Jul 2, 2026 · Common Stock, $0.001 par value · reported falling below 5%, from 5.18% in Feb 6, 2026
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 9.99% in Feb 17, 2026
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.7% in Sep 11, 2025
Cormorant Asset Management, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 9.99% in Feb 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.7% in Sep 11, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed May 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
What KALA reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 31, 2025.
Insider tradesForm 4
6sales
0purchases
0sales on a scheduled plan
5people selling
$200,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 50 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Baker Julian | 10% owner | 4 | $1.1M | 0 | 0 | $0 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 1 | $100,000 | 0 | 0 | $0 |
| Bazemore Todd | President and Chief Executive Officer | 1 | $0 | 0 | 0 | $0 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 2 | $0 | 0 | 0 | $0 |
| Brazzell Romulus K | Head of Research and Development and Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |
| Kharabi Darius | CHIEF BUSINESS OFFICER | 1 | $0 | 0 | 0 | $0 |